Inotuzumab Ozogamicin vs Ipilimumab
Inotuzumab Ozogamicin vs Ipilimumab: Overview
This comparison examines the pharmacological differences between Inotuzumab Ozogamicin and Ipilimumab.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days.
Chemical Properties
Type: Inotuzumab Ozogamicin β Antibody drug conjugate; Ipilimumab β Antibody.